PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection.

PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection.

PfSPZ-CVac combines 'PfSPZ Challenge', which consists of infectious Plasmodium falciparum sporozoites (PfSPZ), with concurrent antimalarial chemoprophylaxis. In a previously-published PfSPZ-CVac study, three doses of 5.12x104 PfSPZ-CVac given 28 days apart had 100% vaccine efficacy (VE) ag...

Full description

Saved in:
Bibliographic Details
Main Authors: Sean C Murphy, Gregory A Deye, B Kim Lee Sim, Shirley Galbiati, Jessie K Kennedy, Kristen W Cohen, Sumana Chakravarty, Natasha Kc, Yonas Abebe, Eric R James, James G Kublin, Stephen L Hoffman, Thomas L Richie, Lisa A Jackson
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-05-01
Series:PLoS Pathogens
Online Access:https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1009594&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1009594&type=printable

Similar Items